RxDoctor Payments Data

Devin Donohoe, PA

Physician Assistant · Greenfield, MANPI 1699190827

Payments from drug & device makers

$272in general payments, 2019–2025

Across 12 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66
  • Alkermes, Inc.$60
  • Teva Pharmaceuticals USA, Inc.$30
  • Takeda Pharmaceuticals U.S.A., Inc.$26
  • Neurocrine Biosciences, Inc.$20
  • Tris Pharma Inc$20
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$22583%
  • Education$4717%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$272 in reported general payments places this provider in the 75th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$47,943
Medicare patients
102
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine30$178,622
Invega SustennaPaliperidone Palmitate29$78,491
VraylarCariprazine Hcl40$68,543
RexultiBrexpiprazole26$33,462
Lurasidone Hcl144$31,855
TrintellixVortioxetine Hydrobromide40$22,988
Risperidone ErRisperidone Microspheres14$22,530
CaplytaLumateperone Tosylate11$17,973
BelsomraSuvorexant31$17,076
Clozapine246$16,053
LunestaEszopiclone14$11,990
Oxcarbazepine217$8,499
Olanzapine278$7,257
Quetiapine Fumarate387$6,167
Perphenazine117$4,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$30$178,62230 claims
Johnson & JohnsonInvega Sustenna$15$78,49129 claims
AbbVieVraylar$16$68,54340 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$33,46226 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$22,98840 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$66$17,97311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Greenfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →